Apollon Wealth Management LLC Sells 1,314 Shares of Kenvue Inc. (NYSE:KVUE)

Apollon Wealth Management LLC lowered its holdings in Kenvue Inc. (NYSE:KVUE) by 11.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,048 shares of the company’s stock after selling 1,314 shares during the period. Apollon Wealth Management LLC’s holdings in Kenvue were worth $232,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Riverview Trust Co acquired a new position in Kenvue in the third quarter valued at about $30,000. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue in the 3rd quarter valued at approximately $35,000. Studio Investment Management LLC lifted its holdings in shares of Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after acquiring an additional 845 shares during the period. Deseret Mutual Benefit Administrators boosted its position in shares of Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Kenvue in the second quarter valued at approximately $61,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on KVUE shares. Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a report on Tuesday, September 24th. Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Jefferies Financial Group initiated coverage on Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Piper Sandler boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $22.64.

Kenvue Trading Down 0.4 %

NYSE:KVUE opened at $23.73 on Tuesday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.13. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $45.50 billion, a price-to-earnings ratio of 43.15, a PEG ratio of 2.16 and a beta of 1.36. The firm has a fifty day simple moving average of $22.77 and a two-hundred day simple moving average of $20.71.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the prior year, the company earned $0.31 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. Analysts expect that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date is Wednesday, November 13th. Kenvue’s dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.